Mitsubishi Tanabe Pharma (MTP-CA) Receives Health Canada Approval of Radicava for Amyotrophic Lateral Sclerosis (ALS)

 Mitsubishi Tanabe Pharma (MTP-CA) Receives Health Canada Approval of Radicava for Amyotrophic Lateral Sclerosis (ALS)

Shots:

  • The Notice of Compliance (NOC) authorization is based on the clinical trial assessing Radicava (edaravone), demonstrating its positive 1EP measured by using the ALSFRS-R
  • Edaravone is a IV medication, received the US FDA PR designation to treat ALS and marketed as Radicava in the US and as Radicut in Japan (IV 30mg) to treat acute stage of cerebral infection
  • In Mar,2018 Mitsubishi Tanabe Pharma America’s (MTPA) subsidiary MTP-CA will process the distribution of RADICAVA in Canada. ALS is idiopathic neurodegenerative disorder with ~2 in 100,000 are affected globaly & and as reported by ALS Society of Canada almost 3,000 Canadians are living with ALS

Click here to read full press release/article | Ref: Mitsubishi Tanabe Pharma | Image: Radicava

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post